Adaptive radiotherapy has been introduced to manage an individual's treatment by, including patient-specific treatment variation identified and quantified during the course of radiotherapy in the treatment planning and delivering optimization. Early studies have demonstrated that this technique could significantly improve the therapeutic ratio by safely reducing the large target margin that has to be used in conventional radiotherapy for prostate cancer treatment. Clinical application of off-line image-guided adaptive radiotherapy for prostate cancer has demonstrated encouraging clinical outcome. Long-term clinical follow-up has shown significant improvement in terms of tumor control and low toxicity profile, emphasizing the beneficial effect of image-guidance and adaptive treatment. Continuous development in adaptive radiotherapy has made possible additional increases in target dose by further reducing target margin when using online image-guided adaptive intensity-modulated radiation therapy. However, clinical implementation of new techniques should be explored cautiously and should include a comprehensive management strategy to address uncertainties in target definition and delineation in the preclinical implementation studies.
Department of Radiation Oncology, William Beaumont Hospitals and Research Institute, Royal Oak, MI
Address reprint requests to Michel Ghilezan, MD, PhD, Department of Radiation Oncology, William Beaumont Hospitals and Research Institute, Royal Oak, MI 48073-6769
Clinical translational research of adaptive radiotherapy for prostate cancer in Radiation Oncology, William Beaumont Hospitals has been supported in part by NCI, Grants: R29 CA71785, R01 CA118037, R01 CA091020, R21 CA130330, and US Army Medical Research, Grants: PC970201, PC061209.
Department of Radiation Oncology in William Beaumont Hospital receives research and development grants from ELEKTA Oncological System and Philips Radiation Oncological System.